Vaccine Strategies in Follicular Lymphoma

During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of using loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell therapy.

David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.

During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell therapy.

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

LBL-007 plus toripalimab showed manageable safety and favorable response in advanced solid tumors, notably higher in IO-naive nasopharyngeal carcinoma. Higher LAG-3 was linked to better responses.

Olalekan O Oluwole, MD, MBBS, discussed a study on cytokine release syndrome and neurological events post axicabtagene ciloleucel in large B-cell lymphoma.